Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3404272 | 1.00 | HTR1A (0.41) | HTR1ADRD2F10SLC6A2SLC6A4 | |
| SCHEMBL9700002 | 0.80 | HPGD (0.34) | SLC6A2SLC6A4SLC6A3KDM4EHPGD | |
| SCHEMBL3791536 | 0.79 | KCNH2 (0.34) | HTR1ADRD2F10 | |
| SCHEMBL3409568 | 0.79 | KCNH2 (0.34) | HTR1ADRD2F10 | |
| SCHEMBL3428210 | 0.78 | HTR1A (0.39) | HTR1ADRD2NISCHKDM4EMAPT | |
| SCHEMBL3408360 | 0.77 | F10 (0.31) | F10 | |
| SCHEMBL3784097 | 0.77 | F10 (0.31) | F10 | |
| SCHEMBL2291274 | 0.74 | HTR1A (0.43) | HTR1ADRD2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11398596 | 0.70 | HTR1A (0.36) | HTR1ADRD2KDM4EMAPT | |
| SCHEMBL2292376 | 0.68 | HTR1A (0.43) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257551-B1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-10 | — | — | EP | disclosed |
| US-8349828-B2 | Azatricyclic antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331318-A1 | AZATRICYCLIC ANTIBIOTIC COMPOUNDS | ZYX, AZI2, NAT1 | HTR1A 1449/4885DRD2 806/4885F10 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.